11:27 AM EDT, 04/28/2025 (MT Newswires) -- Champions Oncology ( CSBR ) said Monday it has obtained a license to use radioactive materials in preclinical studies, expanding its ability to develop and test targeted radiotherapies in-house.

The license allows Champions to integrate radionuclide-based therapeutic testing with its patient-derived xenograft models platform, supporting drug developers across modalities like antibody-radionuclide conjugates and peptide receptor radionuclides, the company said.

Price: 7.94, Change: +0.04, Percent Change: +0.47